Search Page

1

Cite

Share

In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.

Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF. Pillar CM, et al. Among authors: draghi dc. J Clin Microbiol. 2008 Sep;46(9):2862-7. doi: 10.1128/JCM.00637-08. Epub 2008 Jul 2. J Clin Microbiol. 2008. PMID: 18596149 Free PMC article.

Cite

Share

2

Cite

Share

Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci.

Arhin FF, Draghi DC, Pillar CM, Moeck G, Sahm DF. Arhin FF, et al. Among authors: draghi dc. Int J Antimicrob Agents. 2012 Dec;40(6):562-3. doi: 10.1016/j.ijantimicag.2012.06.019. Epub 2012 Aug 4. Int J Antimicrob Agents. 2012. PMID: 22871370 No abstract available.

Cite

Share

3

Cite

Share

Bactericidal activity and resistance development profiling of dalbavancin.

Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF. Goldstein BP, et al. Among authors: draghi dc. Antimicrob Agents Chemother. 2007 Apr;51(4):1150-4. doi: 10.1128/AAC.00620-06. Epub 2007 Jan 12. Antimicrob Agents Chemother. 2007. PMID: 17220411 Free PMC article.

Cite

Share

4

Cite

Share

Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance.

Draghi DC, Tench S, Dowzicky MJ, Sahm DF. Draghi DC, et al. Chemotherapy. 2008;54(2):91-100. doi: 10.1159/000118660. Epub 2008 Feb 25. Chemotherapy. 2008. PMID: 18303257

Cite

Share

5

Cite

Share

Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare.

Jones ME, Goguen J, Critchley IA, Draghi DC, Karlowsky JA, Sahm DF, Porschen R, Patra G, DelVecchio VG. Jones ME, et al. Among authors: draghi dc. Clin Microbiol Infect. 2003 Sep;9(9):984-6. doi: 10.1046/j.1469-0691.2003.00775.x. Clin Microbiol Infect. 2003. PMID: 14616693 Free article.

Cite

Share

6

Cite

Share

Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF. Arhin FF, et al. Among authors: draghi dc. Antimicrob Agents Chemother. 2009 Nov;53(11):4762-71. doi: 10.1128/AAC.00952-09. Epub 2009 Sep 8. Antimicrob Agents Chemother. 2009. PMID: 19738026 Free PMC article.

Cite

Share

7

Cite

Share

Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs.

Pillar CM, Draghi DC, Sheehan DJ, Sahm DF. Pillar CM, et al. Among authors: draghi dc. Diagn Microbiol Infect Dis. 2008 Feb;60(2):221-4. doi: 10.1016/j.diagmicrobio.2007.08.007. Epub 2007 Oct 31. Diagn Microbiol Infect Dis. 2008. PMID: 17976944

Cite

Share

8

Cite

Share

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Draghi DC, et al. Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28. Antimicrob Agents Chemother. 2008. PMID: 18443115 Free PMC article.

Cite

Share

9

Cite

Share

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR Jr, Moeck G. Arhin FF, et al. Among authors: draghi dc. Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25. Antimicrob Agents Chemother. 2008. PMID: 18299406 Free PMC article.

Cite

Share

10

Cite

Share

Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004).

Draghi DC, Jones ME, Sahm DF, Tillotson GS. Draghi DC, et al. Int J Antimicrob Agents. 2006 Dec;28(6):525-31. doi: 10.1016/j.ijantimicag.2006.09.002. Epub 2006 Nov 13. Int J Antimicrob Agents. 2006. PMID: 17101260

Cite

Share